Screener
CRISPR Therapeutics CRSP Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $423,308 | $347,559 |
| Marketable securities | 2,018,477 | 1,628,269 |
| Prepaid expenses and other current assets | 6,577 | 9,843 |
| Total current assets | 2,448,362 | 1,985,671 |
| Property and equipment, net | 112,175 | 115,851 |
| Restricted cash | 7,629 | 7,629 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's cash & equivalents?
- CRISPR Therapeutics (CRSP) reported cash & equivalents of $423.31M in Q1 2026.
- How has CRISPR Therapeutics's cash & equivalents changed year-over-year?
- CRISPR Therapeutics's cash & equivalents increased by 80.0% year-over-year, from $235.18M to $423.31M.
- What is the long-term trend for CRISPR Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's cash & equivalents has grown at a -21.5% compound annual growth rate (CAGR), from $1.17B to $347.56M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about CRISPR Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude